Figure 6. Depletion of CD44 for PDAC relapse treatment.

(A) Gemcitabine treated tumors were transplanted into new mice and allowed to continue to grow (tumor-gem P1), and CD44 expression was evaluated by immunofluorescence and by western blot. (B) Quantification of CD44 expression is shown. (C) AO-IPC xenografts treated with vehicle or gemcitabine (100 mg/kg, biweekly, from days 35 to 85) were then treated with anti-CD44 mAb 200 μg/mice biweekly and tumor volume was monitored weekly (mm³). (D) AO-IPC xenografts were treated with vehicle or anti-CD44 (200 μg/mice biweekly) from days 35 to 85. Scale bar represents 100 μm. Error bars ± SEM; n=3 per group. *P<0.05, **P<0.001 compared to vehicle samples.